PURPOSE OF REVIEW: Targeting immune checkpoints has led to promising results in metastatic nonsmall cell lung cancer (NSCLC). By restoring antitumor immunity, these treatments are able to induce prolonged clinical responses. The level of activity and the durability of responses observed in phase I trials has led most companies to launch phases II and III trials whose results are highly expected. RECENT FINDINGS: In this review, we present efficacy and toxicity results of the different immune checkpoint inhibitors (ICIs) currently developed in NSCLC and report other checkpoints currently explored. The specific profile of tumor responses and immune-related toxicity observed with immunotherapy will be addressed. Finally, to illustrate the new insights into the development of these drugs, we will give an overview of the different ICIs combination studies evaluated in NSCLC and will discuss the role of programmed cell death-L1 as a potential biomarker. SUMMARY: This review will address some of the future challenges of ICIs in NSCLC.
PURPOSE OF REVIEW: Targeting immune checkpoints has led to promising results in metastatic nonsmall cell lung cancer (NSCLC). By restoring antitumor immunity, these treatments are able to induce prolonged clinical responses. The level of activity and the durability of responses observed in phase I trials has led most companies to launch phases II and III trials whose results are highly expected. RECENT FINDINGS: In this review, we present efficacy and toxicity results of the different immune checkpoint inhibitors (ICIs) currently developed in NSCLC and report other checkpoints currently explored. The specific profile of tumor responses and immune-related toxicity observed with immunotherapy will be addressed. Finally, to illustrate the new insights into the development of these drugs, we will give an overview of the different ICIs combination studies evaluated in NSCLC and will discuss the role of programmed cell death-L1 as a potential biomarker. SUMMARY: This review will address some of the future challenges of ICIs in NSCLC.
Authors: Stephanie E Busch; Mark L Hanke; Julia Kargl; Heather E Metz; David MacPherson; A McGarry Houghton Journal: J Immunol Date: 2016-10-31 Impact factor: 5.422
Authors: Ramon Andrade de Mello; Ana Flávia Veloso; Paulo Esrom Catarina; Sara Nadine; Georgios Antoniou Journal: Onco Targets Ther Date: 2016-12-16 Impact factor: 4.147
Authors: Fabio Cofano; Matteo Monticelli; Marco Ajello; Francesco Zenga; Nicola Marengo; Giuseppe Di Perna; Roberto Altieri; Paola Cassoni; Luca Bertero; Antonio Melcarne; Fulvio Tartara; Alessandro Ducati; Diego Garbossa Journal: Cancer Control Date: 2019 Jan-Dec Impact factor: 3.302